Skip to content
Menu

HC Wainwright & Co. Reiterates Buy on Cartesian Therapeutics, Maintains $25 Price Target

Benzinga Newsdesk 2 days ago

Analyst RatingsNewsReiterationPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and maintains $25 price target.

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and maintains $25 price target.

Read at benzinga.com

← All stock news